Ga-68 Somatostatin Receptor PET/CT in von Hippel-Lindau Disease

Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, et al. von Hippel-Lindau disease. Lancet. 2003;361:2059–67.

Leung RS, Biswas SV, Duncan M, Rankin S. Imaging features of von Hippel-Lindau disease. Radiographics. 2008;28:65–79. quiz 323.

Davenport MS, Caoili EM, Cohan RH, Hoff CN, Ellis JH. Pancreatic manifestations of von Hippel-Lindau disease-effect of imaging on clinical management. J Comput Assist Tomogr. 2010;34:517–22.

Hes FJ, Feldberg MA. Von Hippel-Lindau disease: strategies in early detection (renal, adrenal, pancreatic masses). Eur Radiol. 1999;9:598–610.

Prasad V, Ambrosini V, Alavi A, Fanti S, Baum RP. PET/CT in neuroendocrine tumors: evaluation of receptor status and metabolism. PET Clin. 2007;2:351–75.

Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med. 2008;36:228–47.

Melmon KL, Rosen SW. Lindau's disease, review of literature and study of a large kindred. Am J Med. 1964;36:595–671.

Seizinger BR, Rouleau GA, Ozelius LJ, Lane AH, Farmer GE, Lamiell JM, et al. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature. 1988;332:268–9.

Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, et al. Identification of vol Hippel-Lindau disease tumor suppressor gene. Science. 1993;260:1317–20.

Karsdorp N, Elderson A, Wittebol-Post D, Hene RJ, Vos J, Feldberg MA, et al. Von Hippel-Lindau disease: new strategies in early detection and treatment. Am J Med. 1994;97:158–68.

Marcos HB, Libutti SK, Alexander HR, Lubensky IA, Bartlett DL, Walther MM, et al. Neuroendocrine tumors of the pancreas in von Hippel-Lindau disease: spectrum of appearances at CT and MR imaging with histopathologic comparison. Radiology. 2002;225:751–8.

Woodward ER, Maher ER. Von Hippel-Lindau disease and endocrine tumour susceptibility. Endocr Relat Cancer. 2006;13:415–25.

Kaji P, Carrasquillo JA, Linehan WM, Chen CC, Eisenhofer G, Pinto PA, et al. The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome. Eur J Endocrinol. 2007;156:483–7.

Kok J, Lin M, Wong V, Campbell P, Lin P. [18F]FDG PET/CT in pancreatic neuroendocrine tumours associated with von Hippel Lindau Syndrome. Clin Endocrinol (Oxf). 2009;70:657–9.

Ambrosini V, Campana D, Allegri V, Opocher G, Fanti S. 68Ga-DOTA-NOC PET/CT detects somatostatin receptors expression in von Hippel-Lindau cerebellar disease. Clin Nucl Med. 2011;36:64–5.

Kroiss A, Putzer D, Uprimny C, Decristoforo C, Gabriel M, Santner W, et al. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging. 2011;38:865–73.